| Serial Number | 79404692 |
| Word Mark | LISAVEI |
| Filing Date | Wednesday, May 8, 2024 |
| Status | 641 - NON-FINAL ACTION - MAILED |
| Status Date | Thursday, December 12, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 5 - Drawing with word(s) / letter(s) / number(s) in Stylized form |
| Published for Opposition Date | NOT AVAILABLE |
| Goods and Services | Contact lens cleaner; human drug; disinfectant; fungicide; protein supplements; dietetic beverages adapted for medical purposes; nutritional supplements; dietetic substances adapted for medical use; baby milk powder; air purifying preparations. |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, September 19, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Shanghai Meifute Biotechnology Co., Ltd |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | CN |
| Event Date | Event Description |
| Thursday, September 19, 2024 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, September 20, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, September 20, 2024 | APPLICATION FILING RECEIPT MAILED |
| Thursday, November 21, 2024 | ASSIGNED TO EXAMINER |
| Wednesday, November 27, 2024 | NON-FINAL ACTION WRITTEN |
| Thursday, November 28, 2024 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Thursday, December 12, 2024 | REFUSAL PROCESSED BY MPU |
| Thursday, December 12, 2024 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Sunday, December 29, 2024 | REFUSAL PROCESSED BY IB |